On August 28, 2019 Clovis Oncology, Inc. (Nasdaq: CLVS) reported that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 2019 Wells Fargo Healthcare Conference on Thursday, September 5, 2019 at 8:35 AM Eastern Time (Press release, Clovis Oncology, AUG 28, 2019, View Source [SID1234539055]). The conference will be held at the Westin Copley Place in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

On August 28, 2019 Cerus Corporation (Nasdaq: CERS) reported that the Company will participate in two upcoming investor conferences (Press release, Cerus, AUG 28, 2019, View Source [SID1234539054]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present at the Baird 2019 Global Healthcare Conference on Wednesday, September 4, 2019, at 12:15 p.m. EDT. The conference will be held at the InterContinental New York Barclay in New York City.
William ‘Obi’ Greenman and Kevin D. Green, Cerus’ vice president finance and chief financial officer, are scheduled to present at 17th Annual Morgan Stanley Healthcare Conference on Monday, September 9, 2019, at 1:05 p.m. EDT. The conference will be held at the Grand Hyatt New York in New York City.
Live webcasts of the presentations will be available on the Investor Relations page of the Cerus web site at View Source Replays of the presentations will be available for approximately two weeks following the completion of the events.

On august 28, 2019 Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, reported that senior management will participate in three upcoming healthcare investor conferences (Press release, Bellicum Pharmaceuticals, AUG 28, 2019, View Source [SID1234539053]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

2019 Wells Fargo Securities Healthcare Conference
Date/Time: Wednesday, September 4, 2019 at 3:35 p.m. EDT
Location: Boston

Citi’s 14th Annual Biotech Conference
Date: Thursday, September 5, 2019 (one-on-one investor meetings)
Location: Boston

Ladenburg Thalmann 2019 Healthcare Conference
Date/Time: Tuesday, September 24, 2019 at 11:30 a.m. EDT
Location: New York

Live webcasts of the presentations at the Wells Fargo and Ladenburg Thalmann conferences may be accessed from the News & Events section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.

On August 28, 2019 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, reported that the FDA has accepted the company’s IND filing for AGEN1223, a milestone in its partnership with Gilead Sciences, Inc (Press release, Agenus, AUG 28, 2019, View Source [SID1234539051]). This milestone triggers a cash payment of $7.5M.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This announcement represents the third milestone delivered in our collaboration with Gilead this year," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "AGEN1223 is a first-in-class bispecific designed to selectively deplete immune-suppressing cells (regulatory T cells) from the tumor microenvironment while boosting cancer-fighting effector T cells and sparing important peripheral regulatory T cells – an important mechanism not addressed with current therapies."

The collaboration between the two companies was announced in December 2018. Under the terms of the agreement, Agenus received $150 million in upfront cash payment and equity investment and is eligible for approximately $1.7 billion in future fees and milestones.

AGEN1223 is an investigational agent that has not been approved for any uses. Efficacy and safety have not been established.

On August 27, 2019 CERENIS Therapeutics reported following the Extraordinary General Meeting of 21 June 2019, the shareholders of CERENIS Therapeutics approved the proposal for a new company name, which is now ABIONYX Pharma (Press release, ABIONYX Pharma, AUG 27, 2019, View Source [SID1234639900]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Beginning on 29 August 2019, the name, ISIN code and symbol/mnemonic of the share listed on Euronext Paris will be as follows:
– Share name: ABIONYX Pharma (replacing CERENIS Therapeutics)
– ISIN code of the share: FR0012616852 (unchanged)
– Stock symbol / Mnemonic code of the action: ABNX (replacing CEREN).

ABIONYX Pharma is a new generation biotech company that seeks to leverage a rich portfolio of clinical and preclinical programs inherited from the assets of CERENIS Therapeutics, to focus on the discovery and development of innovative therapies.